SFS
RARE icon

Sowell Financial Services’s Ultragenyx Pharmaceutical RARE Stock Holding History

Sowell Financial Services’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-731
Closed -$85K – 2204
2021
Q1 		$85K Sell
731
-73
-9% -$9.94K ﹤0.01% 1437
2020
Q4 		$111K Sell
804
-376
-32% -$44.6K ﹤0.01% 1117
2020
Q3 		$97K Sell
1,180
-760
-39% -$63K ﹤0.01% 985
2020
Q2 		$152K Buy
+1,940
New +$128K 0.01% 820

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Sowell Financial Services's RARE Position: Q2 2021 in Review

Sowell Financial Services sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 731 shares — an estimated $85K sold.

Sowell Financial Services first reported a position in RARE in Q2 2020 and held it in 4 quarters. The position peaked at $152K in Q2 2020. 242 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

  • Sowell Financial Services reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 731 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $85K.
  • Sowell Financial Services first reported a position in Ultragenyx Pharmaceutical in Q2 2020 and held it in 4 quarters.
  • Sowell Financial Services's Ultragenyx Pharmaceutical position peaked at $152K in Q2 2020.
  • 242 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.